Ophthalmology News

Ophthal

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Parravano M et al. – The authors included four studies in this review. The authors found two small studies, comparing pegaptanib with sham or bevacizumab with sham in patients with clinically significant macular oedema (CSMO), that showed results in favour of antiangiogenic therapy but could not reliably demonstrate a benefit. An additional small study compared bevacizumab to photocoagulation in eyes with untreated CSMO and its results also favoured antiangiogenic therapy, but not reliably so. Other comparisons were between bevacizumab and triamcinolone, or between bevacizumab alone and bevacizumab plus triamcinolone in three studies which did not show a difference. Three out of the four studies were at risk of bias. Antiangiogenic treatment was well tolerated in these studies, but since all studies were short–term, the authors were unable to investigate long–term effects as well as risks. Although several studies are ongoing, there is not sufficient high quality evidence on the use of anti–VEGF drugs for the treatment of DMO yet.

Related Articles

Nephrotic Syndrome in Adults: Diagnosis and Management
American Family Physician, 11/12/09    Relevance Score: 86%

Is multifocal ERG a reliable index of macular function after triamcinolone acetonide injection in diffuse diabetic macular edema
European Journal of Ophthalmology, 11/11/09    Relevance Score: 81%

Calpain Inhibitor SNJ-1945 Attenuates Events Prior to Angiogenesis in Cultured Human Retinal Endothelial Cells
Journal of Ocular Pharmacology and Therapeutics, 11/09/09    Relevance Score: 81%

Role of endothelial progenitor cells in diabetes mellitus
Expert Review of Endocrinology & Metabolism, 11/16/09    Relevance Score: 80%

Beyond Glycemic Control: Treating the Entire Type 2 Diabetes Disorder
Postgraduate Medicine, 10/05/09    Relevance Score: 80%

Today in Clinical Pharmacology...keeping you current

Pharmacological and environmental factors in primary angle-closure glaucoma
British Medical Bulletin, 11/25/09

Vitreous Nonsteroidal Antiinflammatory Drug Concentrations and Prostaglandin E2 Levels in Vitrectomy Patients Treated With Ketorolac 0.4%, Bromfenac 0.09%, and Nepafenac 0.1%
Retina, 11/25/09

Infliximab and anterior optic neuropathy
Graefe's Archive for Clinical and Experimental Ophthalmology, 11/23/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address